Genetic Deletion of Sost or Pharmacological Inhibition of Sclerostin Prevent Multiple Myeloma-induced Bone Disease without Affecting Tumor Growth

Multiple myeloma (MM) causes lytic bone lesions due to increased bone resorption and concomitant marked suppression of bone formation. Sclerostin (Scl) levels, an osteocyte-derived inhibitor of Wnt/β-catenin signaling, are elevated in MM patient sera and are increased in osteocytes in MM-bearing mic...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado-Calle, Jesus, Anderson, Judith, Cregor, Meloney D., Condon, Keith W., Kuhstoss, Stuart A., Plotkin, Lilian I., Bellido, Teresita, Roodman, G. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699973/
https://www.ncbi.nlm.nih.gov/pubmed/28529307
http://dx.doi.org/10.1038/leu.2017.152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699973/
https://www.ncbi.nlm.nih.gov/pubmed/28529307
http://dx.doi.org/10.1038/leu.2017.152

Ejemplares similares